Search Results

There are 6919 results for: content related to: Selective RAF inhibitor impairs ERK 1/2 phosphorylation and growth in mutant NRAS , vemurafenib-resistant melanoma cells

  1. The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors

    Pigment Cell & Melanoma Research

    Volume 28, Issue 4, July 2015, Pages: 417–430, Casey G. Langdon, Matthew A. Held, James T. Platt, Katrina Meeth, Pinar Iyidogan, Ramanaiah Mamillapalli, Andrew B. Koo, Michael Klein, Zongzhi Liu, Marcus W. Bosenberg and David F. Stern

    Version of Record online : 6 MAY 2015, DOI: 10.1111/pcmr.12376

  2. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors

    Pigment Cell & Melanoma Research

    Volume 27, Issue 3, May 2014, Pages: 479–484, Kevin J. Basile, Kaitlyn Le, Edward J. Hartsough and Andrew E. Aplin

    Version of Record online : 10 FEB 2014, DOI: 10.1111/pcmr.12218

  3. You have free access to this content
    Society for Melanoma Research 2013 Congress

    Pigment Cell & Melanoma Research

    Volume 26, Issue 6, November 2013, Pages: 932–1019,

    Version of Record online : 24 OCT 2013, DOI: 10.1111/pcmr.12166

  4. You have free access to this content
    Society for Melanoma Research 2012 Congress

    Pigment Cell & Melanoma Research

    Volume 25, Issue 6, November 2012, Pages: 836–903,

    Version of Record online : 19 OCT 2012, DOI: 10.1111/pcmr.12023

  5. You have free access to this content
    2011 International Melanoma Congress

    Pigment Cell & Melanoma Research

    Volume 24, Issue 5, October 2011, Pages: 990–1075,

    Version of Record online : 10 OCT 2011, DOI: 10.1111/j.1755-148X.2011.00909.x

  6. Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain

    Pigment Cell & Melanoma Research

    Volume 27, Issue 1, January 2014, Pages: 124–133, Timothy R. Wagenaar, Leyuan Ma, Benjamin Roscoe, Sung Mi Park, Daniel N. Bolon and Michael R. Green

    Version of Record online : 15 OCT 2013, DOI: 10.1111/pcmr.12171

  7. PTEN regulates IGF-1R-mediated therapy resistance in melanoma

    Pigment Cell & Melanoma Research

    Volume 28, Issue 5, September 2015, Pages: 572–589, Jun Wang, Tobias Sinnberg, Heike Niessner, Rebecca Dölker, Birgit Sauer, Wolfgang E. Kempf, Friedegund Meier, Nick Leslie and Birgit Schittek

    Version of Record online : 16 AUG 2015, DOI: 10.1111/pcmr.12390

  8. You have full text access to this OnlineOpen article
    A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma

    Pharmacology Research & Perspectives

    Volume 3, Issue 2, March 2015, Simone M. Goldinger, Jeannine Rinderknecht, Reinhard Dummer, Felix Pierre Kuhn, Kuo-Hsiung Yang, Lucy Lee, Ruben C. Ayala, Jagdish Racha, Wanping Geng, David Moore, Mei Liu, Andrew K. Joe, Selby Patricia Gil Bazan and Joseph F. Grippo

    Version of Record online : 2 FEB 2015, DOI: 10.1002/prp2.113

  9. Low-concentration vemurafenib induces the proliferation and invasion of human HaCaT keratinocytes through mitogen-activated protein kinase pathway activation

    The Journal of Dermatology

    Volume 42, Issue 9, September 2015, Pages: 881–888, Mi Ryung Roh, Jung Min Kim, Sang Hee Lee, Hong Sun Jang, Kyu Hyun Park, Kee Yang Chung and Sun Young Rha

    Version of Record online : 5 JUN 2015, DOI: 10.1111/1346-8138.12950

  10. You have free access to this content
    Society for Melanoma Research 2014 Congress

    Pigment Cell & Melanoma Research

    Volume 27, Issue 6, November 2014, Pages: 1169–1241,

    Version of Record online : 23 OCT 2014, DOI: 10.1111/pcmr.12317

  11. Improved human bioavailability of vemurafenib, a practically insoluble drug, using an amorphous polymer-stabilized solid dispersion prepared by a solvent-controlled coprecipitation process

    Journal of Pharmaceutical Sciences

    Volume 102, Issue 3, March 2013, Pages: 967–981, Navnit Shah, Raman M. Iyer, Hans-Juergen Mair, Duk Soon Choi, Hung Tian, Ralph Diodone, Karsten Fähnrich, Anni Pabst-Ravot, Kin Tang, Emmanuel Scheubel, Joseph F. Grippo, Sebastian A. Moreira, Zenaida Go, James Mouskountakis, Theresa Louie, Prabha N. Ibrahim, Harpreet Sandhu, Linda Rubia, Hitesh Chokshi, Dharmendra Singhal and Waseem Malick

    Version of Record online : 29 DEC 2012, DOI: 10.1002/jps.23425

  12. You have full text access to this OnlineOpen article
    Systematic analysis of BRAFV600E melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis

    Molecular Systems Biology

    Volume 11, Issue 3, March 2015, Mohammad Fallahi-Sichani, Nathan J Moerke, Mario Niepel, Tinghu Zhang, Nathanael S Gray and Peter K Sorger

    Version of Record online : 26 MAR 2015, DOI: 10.15252/msb.20145877

  13. You have free access to this content
    The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation

    Asia-Pacific Journal of Clinical Oncology

    Volume 10, Issue S3, April 2014, Pages: 1–15, Michael P Brown and Georgina V Long

    Version of Record online : 8 APR 2014, DOI: 10.1111/ajco.12200

  14. You have full text access to this OnlineOpen article
    Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases

    Pigment Cell & Melanoma Research

    Volume 29, Issue 1, January 2016, Pages: 92–100, Heike Seifert, Eishu Hirata, Martin Gore, Komel Khabra, Christina Messiou, James Larkin and Erik Sahai

    Version of Record online : 3 NOV 2015, DOI: 10.1111/pcmr.12424

  15. Vitamin C at high concentrations induces cytotoxicity in malignant melanoma but promotes tumor growth at low concentrations

    Molecular Carcinogenesis

    Volume 56, Issue 8, August 2017, Pages: 1965–1976, Guang Yang, Yao Yan, Younan Ma and Yixin Yang

    Version of Record online : 24 APR 2017, DOI: 10.1002/mc.22654

  16. Developing melanoma therapeutics: overview and update

    Wiley Interdisciplinary Reviews: Systems Biology and Medicine

    Volume 5, Issue 3, May/June 2013, Pages: 257–271, John B. Korman and David E. Fisher

    Version of Record online : 13 FEB 2013, DOI: 10.1002/wsbm.1210

  17. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations

    British Journal of Dermatology

    Volume 173, Issue 4, October 2015, Pages: 1024–1031, R. Sinha, J. Larkin, M. Gore and L. Fearfield

    Version of Record online : 11 OCT 2015, DOI: 10.1111/bjd.13958

  18. You have free access to this content
    That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance

    British Journal of Pharmacology

    Volume 169, Issue 8, August 2013, Pages: 1708–1722, Matthew J Sale and Simon J Cook

    Version of Record online : 26 JUL 2013, DOI: 10.1111/bph.12220

  19. The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics

    The Journal of Clinical Pharmacology

    Volume 54, Issue 4, April 2014, Pages: 368–374, Antoni Ribas, Weijiang Zhang, Ilsung Chang, Keisuke Shirai, Marc S. Ernstoff, Adil Daud, C. Lance Cowey, Gregory Daniels, Elizabeth Seja, Elizabeth O'Laco, John A. Glaspy, Bartosz Chmielowski, Todd Hill, Andrew K. Joe and Joseph F. Grippo

    Version of Record online : 22 JAN 2014, DOI: 10.1002/jcph.255

  20. Vemurafenib skin phototoxicity is indirectly linked to ultraviolet A minimal erythema dose decrease

    British Journal of Dermatology

    Volume 171, Issue 6, December 2014, Pages: 1529–1532, C. Brugière, A. Stefan, C. Morice, E. Cornet, A. Moreau, S. Allouche and L. Verneuil

    Version of Record online : 9 NOV 2014, DOI: 10.1111/bjd.13300